• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Environmental research >Prenatal exposure to perfluoralkyl substances (PFASs) associated with respiratory tract infections but not allergy- and asthma-related health outcomes in childhood
【24h】

Prenatal exposure to perfluoralkyl substances (PFASs) associated with respiratory tract infections but not allergy- and asthma-related health outcomes in childhood

机译：产前暴露于与呼吸道感染相关的全氟烷基物质（PFAS），但与儿童过敏和哮喘相关的健康结局无关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Prenatal exposure to perfluoralkyl substances (PFASs) has been reported to be associated with immunosuppression in early childhood, but with contradictory findings related to atopic and lung diseases. Aim We aimed to determine if prenatal exposure to PFASs is associated with asthma or other allergic diseases or respiratory tract infections in childhood. Methods: Nineteen PFASs were measured in cord blood available from 641 infants in the Environment and Childhood Asthma (ECA) prospective birth cohort study. The six most abundant PFASs were perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorooctanesulfonamide (PFOSA), perfluorohexane sulfonic acid (PFHxS), perfluorononanoic acid (PFNA), and perfluoroundecanoic acid (PFUnDA). Health outcomes were assessed at two and ten years of age, and included reported obstructive airways disease (wheeze by 10 years; asthma by 2 and 10 years; reduced lung function at birth; allergic rhinitis by 10 years), atopic dermatitis (AD) by 2 and 10 years, allergic sensitization by 10 years, and episodes of common respiratory tract infections (common cold by 2 years, lower respiratory tract infections (LRTI) by 10 years). The associations between exposure and health outcomes were examined using logistic and Poisson regression. Results: The number of reported airways infections were significantly associated with cord blood concentrations of PFAS; common colds by two years with PFUnDA (P = 0.11 (0.08-0.14)) and LRTIs from 0 to 10 years of age with PFOS (β = 0.50 (0.42-0.57)), PFOA (β = 0.28 (0.22-0.35)), PFOSA (β = 0.10 (0.06-0.14)), PFNA (β = 0.09 (0.03-0.14)) and PFUnDA (β = 0.18 (0.13-0.23)) concentrations. Neither reduced lung function at birth, asthma, allergic rhinitis, AD nor allergic sensitization were significantly associated with any of the PFASs. Conclusion: Although prenatal exposure to PFASs was not associated with atopic or lung manifestations by 10 years of age, several PFASs were associated with an increased number of respiratory tract infections in the first 10 years of life, suggesting immunosuppressive effects of PFASs.
机译：背景技术据报道，产前暴露于全氟烷基物质（PFAS）与儿童早期的免疫抑制有关，但与特应性和肺部疾病相关的发现相互矛盾。目的我们的目的是确定婴儿期产前接触PFAS是否与哮喘或其他过敏性疾病或儿童期呼吸道感染有关。方法：在环境和儿童哮喘（ECA）前瞻性出生队列研究中，对来自641名婴儿的脐带血中的19种PFAS进行了测量。六种最丰富的PFAS是全氟辛烷磺酸（PFOS），全氟辛酸（PFOA），全氟辛烷磺酰胺（PFOSA），全氟己烷磺酸（PFHxS），全氟壬酸（PFNA）和全氟十一烷酸（PFUnDA）。在2岁和10岁时评估健康结局，包括报告的阻塞性气道疾病（喘息10年；哮喘2和10年；出生时肺功能下降；过敏性鼻炎10年），特应性皮炎（AD） 2年和10年，变态反应致敏10年，发作常见呼吸道感染（普通感冒2年，下呼吸道感染（LRTI）10年）。使用logistic和Poisson回归检查暴露与健康结果之间的关联。结果：报告的气道感染数量与脐带血PFAS浓度显着相关。 PFUnDA（P = 0.11（0.08-0.14））感冒两年，0至10岁的LRTIs PFOS（β= 0.50（0.42-0.57）），PFOA（β= 0.28（0.22-0.35）） ，PFOSA（β= 0.10（0.06-0.14）），PFNA（β= 0.09（0.03-0.14））和PFUnDA（β= 0.18（0.13-0.23））浓度。出生时的肺功能降低，哮喘，变应性鼻炎，AD和变态反应致敏均与任何PFAS均无显着相关性。结论：尽管到10岁时，产前暴露于PFAS并不与特应性或肺部疾病相关，但在出生后的头10年中，有几种PFAS与呼吸道感染数量增加相关，提示PFAS具有免疫抑制作用。

著录项

  • 来源
    《Environmental research》 |2018年第1期|518-523|共6页
  • 作者

    A. Impinen; U.C. Nygaard; K.C. Lodrup Carlsen; P. Mowinckel; K.H. Carlsen; L.S. Haug; B. Granum;

  • 作者单位

    Division for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway;

    Division for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway;

    Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway;

    Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway;

    Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway;

    Division for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway;

    Division for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Perfluoralkyl substances; Immunotoxicity; Asthma; Allergy; Infections; Children;

    机译：全氟烷基物质;免疫毒性哮喘;过敏;感染;小孩儿;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号